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Background: Copy-number variation (CNV), rather than complete loss of gene function, is increasingly implicated
in human disease. Moreover, gene dosage is recognised as important in tumourigenesis, and there is an increasing
realisation that CNVs may not be just symptomatic of the cancerous state but may, in fact, be causative. However,
the identification of CNV-related phenotypes for mammalian genes is a slow process, due to the technical difficulty
of constructing deletion mutants. Using the genome-wide deletion library for the model eukaryote, Saccharomyces
cerevisiae, we have identified genes (termed haploproficient, HP) which, when one copy is deleted from a diploid
cell, result in an increased rate of proliferation. Since haploproficiency under nutrient-sufficient conditions is a novel
phenotype, we sought here to characterise a subset of the yeast haploproficient genes which seem particularly
relevant to human cancers.
Results: We show that, for a subset of HP genes, heterozygous deletion is sufficient to cause aberrant cell cycling
and altered rates of apoptosis, phenotypes associated with cancer in mammalian cells. A majority of these yeast
genes are the orthologs of mammalian cancer genes, and hence our studies suggest that CNV of these oncogenic
orthologs may be sufficient to lead to tumourigenesis in human cells. Moreover, where not already implicated, this
cluster of cancer-like phenotypes in this model eukaryote may be predictive of the involvement in cancer of the
mammalian orthologs of these yeast HP genes. Using the yeast set as a model, we show that the response to a
range of anti-cancer drugs is strongly dependent on gene dosage, such that intermediate concentrations of the
drugs can actually increase a mutant’s growth rate.
Conclusions: The exploitation of data on the phenotypic impact of heterozygosis in Saccharomyces cerevisiae has
permitted the prediction of CNVs affecting tumourigenesis in humans. Our yeast data also suggest that the
identification of CNVs in tumour cells may assist both the selection of anti-cancer drugs and the dosages at which
they should be administered if they are to be a beneficial, rather than a deleterious, therapy.
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There is an increasing realisation that copy-number
variation, and in particular the loss of one copy of a gene
from a diploid cell or organism, can have a significant
phenotypic impact. Moreover, the importance of gene
dosage in tumourigenesis is becoming increasingly
recognised [1], and the widespread aneuploidy and copy-
number variations (CNVs) that are the hallmarks of* Correspondence: steve.oliver@bioc.cam.ac.uk
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distribution, and reproduction in any mediumcancer cells are coming to be seen as potentially causa-
tive, rather than simply symptomatic [2-4]. Identifying
causal CNV-related phenotypes for mammalian genes,
however, is hampered by the difficulty in constructing
deletion mutants in the higher Eukaryotes, and the fact
that homozygous knockout (or complete RNAi knock-
down) phenotypes do not necessarily correlate with
those elicited by the loss of a single copy of a gene
[5,6].
In the model eukaryote Saccharomyces cerevisiae, in
contrast, high-throughput screens on whole-genome li-
braries have facilitated the identification of yeast genesentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tion. A screen of > 5,800 deletion mutants, each hetero-
zygous for a different protein-encoding gene in the S.
cerevisiae genome, revealed that over 18% of these
heterozygotes displayed a significantly reduced growth
rate [7]. This haploinsufficient phenotype was displayed
even under conditions where there are no external
constraints (such as nutrient limitations) on cell growth
[8]. For a smaller set (ca. 600 genes, listed in Additional
file 1: Table S1) of ‘haploproficient’ genes, however, het-
erozygous deletion of the gene elicits significantly faster
growth than the wild type. Using these yeast phenotypes,
we have previously made correct predictions of a gene-
dosage-related phenotype for their orthologous human
genes [9], and verified these predictions by controlled
RNAi knockdown in human cell lines [10].
The existence of haploproficient genes in the yeast
genome indicates that the organism has not evolved to
maximize its rate of growth, even when sugars became
abundantly available with the emergence of flowering
plants approximately 80–100 million years ago [11]. The
persistence of these genes in the yeast genome therefore
suggests that there must be some major selective advan-
tage that outweighs their growth-rate disadvantages. We
demonstrate, here, that this advantage could be the
maintenance of genome integrity, which is compromised
when the dosage of these genes is reduced. For HP yeast
genes, the altered gene dosage not only increases growth
rate but, as we will show, copy-number reduction, as
opposed to complete gene deletion, is sufficient to result in
abnormal progression through the cell cycle, increased
accumulation of DNA damage, and altered rates of apop-
tosis. This set of phenotypes is strongly reminiscent of
cancer in mammalian cells. These results complement the
recent conclusions from a study of aneuploid yeast strains
[12] that the detriment to genome stability is driven by
gene-dosage effects (e.g. stoichiometric imbalances), rather
than simply by the presence of extra DNA (or additional
centromeres; [13]). This emphasises the value of using
model organisms to predict which human genes may
impact on cancer in a dosage-dependent manner.
The screening of a library of yeast heterozygous dele-
tion mutants for haploinsufficient or -proficient pheno-
types is a high-throughput approach to determine what
effects quantitative changes in the concentrations of
gene products have on phenotype. A related approach is
the search for drug-induced haploinsufficiency – in
which heterozygous deletion strains exhibit altered
sensitivity to a compound as a result of the decrease in
the dosage of the target gene. In a pioneering study, [14]
exposed a pool of 233 heterozygous mutants to sub-lethal
compound concentrations, and later work has successfully
elucidated the mode-of-action of novel compounds such
as the anti-tumour agent dihydromotuporamine C [15],demonstrating the utility of such genome-wide yeast
screens. In the light of our findings on haploproficiency in
yeast, we combined both approaches and carried out a
screen of anti-cancer agents against a set of S. cerevisiae
mutants heterozygous for HP genes involved in the DNA
damage response-pathway in order to search for altered
sensitivities relative to both the WT and the correspond-
ing homozygous (null) deletion mutant. This screen might
inform both the appropriate treatment of tumour cells
that carry CNVs of the candidate cancer-related genes,
and also suggest novel combinations of specific inhibi-
tors which may prove more effect than either drug in
isolation.
Results
Yeast haploproficient genes are involved in the
maintenance of genome integrity and are orthologs of
human cancer genes
The existence of haploproficient genes, and the inference
that the yeast genome has not been optimised for maximal
growth rate, does not appear to be an accident, nor unique
to S. cerevisiae. By examining orthology relationships across
the Ascomycetes, we find that haploproficient genes are
more highly conserved than the genome average across the
lineage (Fischer’s exact test; p < 0.01) (Table 1a). Thus,
selective pressure has existed toward the retention of HP
genes for several hundred million years (the evolutionary
distance between S. cerevisiae and Sz. pombe), including
through a period of strong selective pressure toward
maximizing growth rate that occurred at the time of
the whole-genome duplication in the Saccharomyces
lineage (approximately 100 million years ago [16]).
Congruent with our hypothesis of a trade-off between
genome stability and growth rate optimisation, we find
that haploproficient genes are overrepresented amongst
those involved in the maintenance of genome integrity. A
Gene Ontology term-enrichment revealed that the HP
set is enriched for genes involved in the mitotic cell
cycle (p = 0.003), and, in particular, the response to and
repair of DNA damage (p = 0.006) (Figure 1; Additional
file 2: Table S2). Given their integral role in maintaining
genome stability, it is unsurprising that yeast HP genes are
very much more likely to be orthologous to cancer genes
than the S. cerevisaie genome average (p < 10-10).
We selected the 30 HP genes (Table 2) involved in the
processes of DNA damage repair and sister chromatid
segregation as the most relevant candidates in which to
examine the relationship between varying gene dosage
and cancer-related phenotypes. This ‘HP genome integrity’
(HPGI) set is even more highly conserved than the HP set
as a whole (Table 1b); and more likely (than the HP set as
a whole) to be orthologous to a cancer gene (p < 10-4).
Nineteen genes in the set have a unique human ortholog
(Table 2) and, of these, 12 (UBX4, IDP1, IDP2, MSH2,
Table 1 a.) P-values of enrichment of haploproficient
genes amongst those S.cerevisae genes having orthologs
in Ascomycete species; b.) P-values for the enrichment of
the subset of S.cerevisiae genes involved in the cell cycle
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are orthologous to cancer genes as annotated in the Cancer
Gene Index (CGI [17]). Table 2 lists the cancer-specific
OMIM disease associations of the orthologs of members of
the HPGI set.
Orthologs of haploproficient genes exhibit CNV in tumour
cells
The haploproficiency phenotype is, by definition, linked to
a reduction in gene copy number. Our hypothesis posits
that it is copy number variation (specifically, a reduction
in gene copy number) of the orthologs of these genes that
is relevant to human cancer. To determine the rate of
incidence of CNV in orthologs of our HP cell cycle set, we
queried our list against the NCI’s Cancer Genome Atlas
database (TCGA [17]). No less than 17/19 of the human
orthologs of the HPGI set have a copy number log2 ratio of
magnitude >0.5 across eight types of cancer. In particular,
12/19 have a copy number reduction (i.e. a log2 ratio
of < −0.5) in >25% of patients in one or more of the eight
cancer types. This is a significant overrepresentation com-
pared with 7750/~18500 of all genes in TCGA (p = 0.07),
and with the set of non-HP cell-cycle/DNA repair orthologs
(p = 0.05). For serous cystadenocarcinoma, kidney renal
clear cell, and lung squamous cell carcinomas, there is a
significant overrepresentation of orthologs of the HPGI set
amongst genes exhibiting frequent copy-number reduction
(p-values of 2 × 10-4, 10-4 and 10-3 respectively). Moreover,
across all eight cancer types, orthologs of the HPGI set are
overrepresented with a p-value of 0.003 (all corrected for
multiple testing).
CNV of haploproficient genes is sufficient to elicit cancer-like
phenotypic responses in yeast
Cell cycle phasing
As their growth rate is higher than the previously observed
maximum, heterozygous deletion mutants of HP genes
must a priori progress faster through the cell cycle. Either
progress through all the phases of the cycle may be acceler-
ated, or one or more phases must be relatively shorter than
in a diploid cell with two copies of the gene. Since the
products of HPGI genes are involved in checkpoint con-
trols of the cell cycle, we reasoned that the faster cycle time
in the heterozygotes could be the result of cells skipping a
compromised checkpoint and therefore progressing faster
through that phase of the cycle. This would manifest itself
in an altered population distribution between the different
cell cycle phases. This same cell cycle dysregulation, arising
from compromised tumour suppressor gene function, is a
mechanism of oncogenesis in mammalian cells [18]. Previ-
ously, we found strong support for the hypothesis that
changes in the copy number of the high flux control (HFC)
genes alter cell cycle progression in a combined modelling/
experimental study of a set of genes involved in the G2/M
Figure 1 Haploproficient genes. The incidence of genes identified in genome-wide deletion library screens [8] as haploproficient within the S.cerevisiae
cell cycle (haploproficient genes highlighted in red) (pathway diagram derived from the KEGG database [45]). Abbreviations: APC = anaphase promoting
complex; SCF = Sck1-Cdc53/CUL-F Box receptor E3 complex; MCM = minichromosome maintenance complex; ORC = origin recognition
complex; PP2A = protein phosphatase 2 complex. Haploproficient members of the complexes are listed in Additional file 2: Table S2.
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haploproficiency and cell cycling is also borne out in
our finding that copy-number variation of HP genes
has no significant effect on yeast chronological lifespan;
that is, survival in the extended non-cycling G0 state of
stationary phase (see Additional file 3: Table S3).
Using flow cytometry, we analysed the cell cycle progres-
sion of heterozygous deletion mutants of the HPGI set,
comparing them with the cell cycle profiles of the WT and
of the non-cell cycle, non-HP controls HIS3/his3 and HO/
ho, non-HP, cell-cycle HSL1/hsl1, CLB2/clb2, CLB5/clb5,
CLB6/clb6, CLN2/cln2 and CLN3/cln3 and the non-cell
cycle genes PNP1, MET7, HRK1 and TPO3. To distinguish
between the effects of the complete absence of a given gene
from those of reducing its copy number from two to one,
we also compared the cycle profiles of the heterozygous
deletant against that of the diploid homozygous deletants
of the same gene. Complete cell cycle profile data is given
in Additional file 4: Table S4.
We find that correct dosage of the HPGI genes is
essential for normal cell cycling: heterozygous deletion is
indeed sufficient to significantly alter the cell cycle profile
relative to the WT/non-cell cycle control genes for 13 ofthe 30 HPGI genes (summarised in Table 3). Typically,
the cell cycle perturbation for the heterozygote concurs
with that previously reported for haploid null deletants
of the gene (as annotated in SGD [19]), however BUB2
heterozygous deletion confers the opposite phenotype
(an decrease in the relative G1 population) to that of
both the null diploid and haploid.
Apoptosis rate
In mammalian cells, compromising the link between the
DNA damage response and apoptotic pathways can
diminish the apoptotic response [20], which is a necessary
step en route to cancer [21]. Therefore, we carried out
tests to determine whether compromising the DNA
damage response in yeast by heterozygous deletion of
HPGI genes affected the rate of apoptosis (see [22] for a
review of S.cerevisiae programmed cell death). The degree
of apoptosis occurring in the deletion strain populations,
in response to treatment with methyl methanesulfonate
(MMS) or tert-butyl hydroperoxide (TBHP). was measured
by simultaneous annexin V (cell surface phosphatidylserine
[23]) and propidium iodide (cell viability) staining [24] to
distinguish between apoptotic and necrotic cells. For 15 of
Table 2 Yeast genes comprising the Haploproficient Genome-Integrity (HPGI) set, along with their unique human





Human ortholog function & OMIM cancer
association (where applicable)
Yeast gene product cell cycle-related function
BUB2 - - Mitotic exit network regulator; blocks cell cycle progression
before anaphase in response to spindle and kinetochore damage
CCR4 CNOT6 CCR4-NOT transcription complex, subunit 6 Component of the CCR4-NOT transcriptional complex
CDC34 UBE2R2 Ubiquitin-conjugating enzyme E2R 2 Ubiquitin-conjugating enzyme (E2) and catalytic subunit of
SCF ubiquitin-protein ligase complex that regulates cell cycle
progression by targeting key substrates for degradation
CHK1 CHEK1 Serine/threonine kinase and DNA damage checkpoint effector Serine/threonine kinase and DNA damage checkpoint effector
CLB1 CCNB1 Cyclin B1 B-type cyclin involved in cell cycle progression; activates
Cdc28p to promote the transition from G2 to M phase
CTF8 CHTF8 Subunit of a complex with Ctf18p that shares some
subunits with Replication Factor C and is required for
sister chromatid cohesion
Subunit of a complex with Ctf18p that shares some subunits with
Replication Factor C and is required for sister chromatid cohesion
DBF2 - - Ser/Thr kinase involved in transcription and stress response;
functions as part of a network of genes in exit from mitosis.
DNL4 LIG4 DNA ligase required for non-homologous end-joining;
OMIM: Lig4 syndrome
DNA ligase required for nonhomologous end-joining (NHEJ)
IDP1 IDH1 Isocitrate dehydrogenase 1 (NADP+); OMIM:
Oligodendroglioma; piloytic astrocytoma
Mitochondrial NADP-specific isocitrate dehydrogenase,
catalyzes the oxidation of isocitrate to alpha-ketoglutarate
IRR1 STAG1 Stromal antigen 1 Subunit of the cohesin complex, required for sister chromatid
cohesion during mitosis and meiosis
MAD1 MAD1L1 Component of the spindle-assembly checkpoint Coiled-coil protein involved in the spindle-assembly
checkpoint; forms a complex with Mad2p
MEU1 MTAP Methylthioadenosine phosphorylase; OMIM: Glioma Methylthioadenosine phosphorylase
MLH1 MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 Protein required for mismatch repair in mitosis
MSH2 MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1;
OMIM: colorectal cancer
Protein required for mismatch repair in mitosis
MUS81 MUS81 MUS81 endonuclease homolog; OMIM: Bloom syndrome
(predisposition to leukemias, lymphomas & carcinomas)
Subunit of the Mms4p-Mus81p endonuclease that cleaves
branched DNA; involved in DNA repair, replication fork stability
RAD1 ERCC4 Excision repair cross-complementing rodent repair deficiency,
complementation group 4; OMIM: Xeroderma pigmentosum
(predisposition to basal cell carcinoma & melanoma)
Single-stranded DNA endonuclease (with Rad10p), cleaves
single-stranded DNA during nucleotide excision repair and
double-strand break repair
RAD54 RAD54L RAD54-like; OMIM: Lymphoma, non-Hodgkin DNA-dependent ATPase, stimulates strand exchange by
modifying the topology of double-stranded DNA;
recombinational repair of double-strand breaks in DNA
RAD61 - - Subunit of a complex (Scc3p, Pds5p, Rad61p) that inhibits
sister chromatid cohesion
RAD9 RAD9 - DNA damage-dependent checkpoint protein, required for
cell-cycle arrest in G1/S, intra-S, and G2/M; transmits
checkpoint signal by activating Rad53p and Chk1p
SMC2 SMC2 Structural maintenance of chromosomes 2 Subunit of the condensin complex
STP22 TSG101 Tumor susceptibility gene 101; OMIM: Breast cancer Component of the ESCRT-I complex
TOP1 TOP1 Topoisomerase (DNA) I Topoisomerase I
TOP2 TOP2B Topoisomerase (DNA) II beta 180kDa Topoisomerase II
TPD3 PPP2R1B Protein phosphatase 2, regulatory subunit A, beta;
OMIM: Lung cancer
Regulatory subunit A of the heterotrimeric protein
phosphatase 2A (PP2A)
TUM1 TST Thiosulfate sulfurtransferase (rhodanese); OMIM: Tumours Rhodanese domain sulfur transferase
UBX4 ASPSCR1 Alveolar soft part sarcoma chromosome region,
candidate 1; OMIM: Alveolar soft-part sarcoma
UBX (ubiquitin regulatory X) domain-containing protein
that interacts with Cdc48p
YCG1 NCAPG non-SMC condensin I complex, subunit G Subunit of the condensin complex
RIM11 GSK3A Glycogen synthase kinase 3 alpha Protein kinase required for signal transduction during entry
into meiosis
NBP2 SH3GL1 SH3-domain GRB2-like 1; OMIM: Acute myeloid leukemia Protein involved in the HOG (high osmolarity glycerol)
pathway, contains an SH3 domain that binds Pbs2p
PBS2 MAP2K1 MAP kinase kinase MAP kinase kinase of the HOG signaling pathway;
mediates cell cycle arrest
de Clare and Oliver BMC Biology 2013, 11:24 Page 5 of 15
http://www.biomedcentral.com/1741-7007/11/24
Table 3 Cell cycle phenotypes of those deletion strains
having a cycle profile significantly distinct from the
wild-type
Cell cycle phenotype Genotype
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exhibited a degree of apoptosis significantly different
(p < 0.05) from than the WT – that is, partial knock-
down of the gene expression is sufficient to disrupt the
normal apoptotic response of the cell. Whilst exploring
the specific mechanisms behind this disruption for
each gene is beyond the scope of this paper, it is clear
that deviating from the WT dosage of these particular
genes has a significant effect on programmed cell death in
response to genotoxic agents. Phenotypes for the mutants
are described in Table 4; apoptosis rates in HIS3/his3Δ
and HO/hoΔ control strains are comparable to WT.
The phenotypes observed for the HPGI heterozygous
deletants were compared with those reported in the
literature for the RNAi-mediated knockdown or pharma-
cological inhibition of their mammalian orthologs. The
congruence between the yeast and mammalian phenotypes
is summarized in Table 4. For 2/4 cases of increased apop-
tosis upon copy-number reduction, the phenotype is also
observed in human cells, however for MLH1/MLH1 and
UBX4/ASPSCR1 the relationship between gene dosage and
apoptosis in human cells is acknowledged, but unclear [32].
Similarly, for 4/11 genes prompting reduced apoptosis
upon copy-number reduction, knockdown of the human
ortholog has been reported to cause a similar phenotype;
we could find no report for the orthologs of a further 5
of the 11. For SMC3/SMC3 and DNL4/LIG4, however,
copy-number reduction in yeast reduced apoptosis, whilstknockdown in mammalian systems has been reported to
increase its occurrence [28,29]. However, both of these
reports involve a complete deletion of the gene, rather
than the heterozygous deletion in which we observed the
yeast phenotype. This suggests that further investigation
in human cells of the effects of varying gene dosage of
these genes, in particular, would be worthwhile.
Haploproficiency & cancer drug sensitivity
Given the strong connection that we have observed
between yeast haploproficiency and human cancer, it is
unsurprising that the human orthologs of many of the
HPGI genes are the targets of various anti-cancer com-
pounds (both approved drugs and those in late-stage
clinical trials; see Table 5). However, in the light of the
increased growth upon reduction of HP gene dosage,
and the dosage-specific phenotypes reported above, it is
possible that inhibitor treatment of a tumour cell could
elicit the opposite to the desired response – i.e. increased
proliferation rather than cell death – if complete ablation
of the HP target function is not achieved. Therefore, we
examined the drug sensitivity of wild-type yeast, and the
heterozygous and homozygous deletion mutants for
each of the non-essential HPGI genes. We also
included the deletion mutants for an additional five
yeast genes (HRK1, TPO3, MET7, PNP1 and GPD1),
which are HP and whose products are orthologous to
specific cancer-drug targets.
Where the human ortholog of a yeast HPGI gene
product is a cancer-drug target (Table 5) we included in
our screen either the commercial drug (where available)
or alternative inhibitors (for example, PD98059 for Pbs2p).
In total, 18 drugs were screened (see Table 5): two of
these were specific alternative inhibitors; 15 were com-
pounds either approved for human cancer treatment
or shown to be effective in cell culture; and one control
treatment of clotrimazole, a fungicide not known to
have anti-cancer properties.
Drug sensitivity profiles were clustered (Figure 2 left
panel) by agglomerative hierarchical clustering [33]. The
profile elicited by a compound can reveal its mode of ac-
tion, and thus similarities between drug profiles may indi-
cate the targeting of the same pathways in yeast.
Reassuringly, known modes of action are reflected in our
profiles – for example, the sensitivity of cell wall integrity/
morphogenesis deletion mutants to phleomycin (Figure 2
left panel), which causes cell wall lesions [34].
Control (non-cancer drug) clotrimazole treatments are
reasonably distinct from the cancer drug treatments.
Aminopterin and methotrexate (which share a common,
antifolate, mechanism of action) PD98059, cycloheximide
and mitoxantrone cluster together, driven largely by the
resistant phenotypes of deletion mutants of genes
involved in chromosome condensation and segregation
Table 4 Observed apoptotsis-related phenotypes of our HP yeast genes compared with those of their human orthologs
HP yeast gene Human
ortholog
Apoptotic phenotype (% dead cells) of yeast
heterozygous deletion mutants treated with MMS.
(Change in rate of apoptosis, relative to WT, is
significant at p< 0.05 for all yeast heterozygotes.)
Mammalian apoptosis-related phenotype
from literature
0.01% MMS 0.001% MMS
WT - 79% 68%
CTF8 CHTF8 49% - -
MSH2 MSH2 56% - RNAi-mediated knockdown decreases apoptosis [25]
MUS81 MUS81 56% - -
TPD3 PPP2R1B 60% - RNAi-mediated knockdown decreases apoptosis [26]
TOP1 TOP1 55% - RNAi-mediated knockdown reduces nuclear apoptosis [27]
RAD54 RAD54L 44% -
SMC3 SMC3 - 30% RNAi-mediated knockdown increases apoptosis [28]
RAD1 ERCC4 - 22% -
DNL4 LIG4 - 46% Extensive apoptosis in mouse deletion homozygotes [29]
MAD1 MAD1L1 - 20% -
MEU1 MTAP - 94% Pharmacological targeting of MTAP promotes apoptosis [30]
MLH1 MLH1 - 93% Abnormal apoptosis (OMIM)
CHK1 CHEK1 - 82% Blocking CHK1 induces apoptosis [31]
UBX4 ASPSCR1 - 80% Regulator of apoptosis (OMIM)
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is formed by Bay11, cantharidin and vorinostat
(SAHA), all of which act as inhibitors of the NF-κB
pathway in mammalian cells [35-37]. This pathway is
absent in S.cerevisiae [38] however, the clustering of
the compounds suggests that their modes of action,
though distinct from the mammalian-cell pathway,
may also be related in yeast. rad54/rad54 mutants are
particularly resistant to all three drugs, where, in general,
these mutants are sensitive to all other treatments.
Vorinostat has been demonstrated to induce DSBs in acute
myeloid leukemia cells [39], suggesting that the DSB-repair
function of Rad54p could potentially be a target. Indeed,
the RAD54 ortholog, RAD54L, is strongly down-regulated
in LNCAP (prostate adenocarcinoma) cells treated with
vorinostat [40]. This is also the case for the mammalian
orthologs of CHK1 and TOP2, which are also resistant
(though less strongly so) to the vorinostat /Bay11/can-
tharidin cluster. We have since demonstrated [10] that
the magnitude of these drug-response phenotypes in
yeast (deviations of up to ±20% of WT growth rate) is
sufficient to translate into observable phenotypes in
tumour cell lines.
Targeting the CNV profile of tumour cells
Where a copy of a gene is frequently lost in tumour
cells, as is the case for orthologs of the HPGI set, the
phenotype of the heterozygous deletion mutant of the
yeast ortholog might better reflect the tumour cell’s
response to drug treatment (Figure 3b). For a significant
number of homozygous/heterozygous deletant pairs(9/30, p = 0.01) the drug sensitivity phenotypes are quanti-
tatively dissimilar (by Euclidean squared distance, i.e. diver-
ging at the top level of branching) (Figures 2 left and right
panel). For these genes, therefore, gene dosage may be
highly relevant to pharmaceutical efficacy. These eight
genes (CCR4, TOP1, IDP1, RAD54, BUB2, MUS81, PNP1,
and MAD1) have, on average, a greater number of
protein-protein interactors (as annotated in BioGrid
[41]) than the average for our HPGI set as a whole (180
unique interactors versus 135). This suggests that gene
dosage balance may be an important contributor to
phenotype for genes which are more central in interaction
networks. We have explored the relationship between
gene copy number and drug response further in [8].
Previously, we reported the striking result that treatment
of wild-type yeast with low concentrations of inhibitors
targeting HP genes can induce the same increased prolifer-
ative phenotype as is observed upon reducing the copy
number of the HP target, a phenomenon we termed
hypertolerance [8]. We observe this phenotype again
for treatment with cantharidin, which inhibits the
PP2A complex, the subunits of which are strongly
haploproficient (Additional file 5: Table S5), but not
for any of the general cytotoxic compounds in the drug
screen, reinforcing our previously-established link be-
tween the specific inhibition of a haploproficient target
and drug hypertolerance. A number of heterozygous
strains also exhibited hypertolerance in solid-media
screens, which was subsequently confirmed by titrating
across a range of drug concentrations in liquid medium
(Table 5). For tumour cells bearing the orthologous











Cancer in which CNV-reduction
of the gene deletedin the
hypertolerant strain occurs
Cycloheximide 0.36, 1.8 0.1 Inhibition of translation
RAD54/RAD54L
IRR1/irr1 -RIM11/GSK3B
Mitoxantrone 10, 25 - TOPII inhibition TOP2/TOP2A - -
Methotrexate 200 2, 100 Inhibition of nucleoside and purine synthesis MET7/FPGS
NBP2/nbp2
Serous adenocarcinoma (NBP2)GPD1/gpd1
RIM11/rim11 Renal cell carcinoma (GPD1)
Phleomycin 1, 2 0.1, 0.5 DNA strand break induction - MET7/met7 Serous adenocarcinoma
5-fluorouracil 200 2, 100 Inhibition of pyrimidine synthesis - IDP1/idp1 -
Tamoxifen 25 - Estrogen receptor antagonist - - -
Aminopterin 10 0.1,1, 5, 10, 50, 100 Inhibition of DNA, RNA & protein synthesis -
NBP2/nbp2
Serous adenocarcinomaTOP1/top1
SAHA/vorinostat 10, 20 - Histone deacetylase inhibition RPD3/HDAC2 - -
Bay 11-7085 20, 40 - NF-kB TF inhibitior; proapoptotic agent - - -
Cantharidin 30, 60 6, 30 Inhibition of PP2A TPD3 UBX4/ubx4 -
PD98059 (2'-amino-3'-methylflavone) 40, 80 4 MEK1 MAPK inhibition PBS2/MAP2K1 NBP2/nbp2 Serous adenocarcinoma
Hydroxyurea 100000, 200000 100, 1000 Inhibition of DNA synthesis; DSB induction RAD54/RAD54L
MLH1/mlh1
Renal cell carcinoma (MLH1)
HRK1/hrk1
STP22/stp22
Lithium chloride - Alternative RIM11 inhibitor RIM11/GSK3B -
Caffeine 1000, 5000 - Alternative RAD54 inhibitor RAD54/RAD54L -
Methyl methanesulfonate -
DNA methylation, causing DSB or stalled
replication forks - -
DPI 10, 20 - NAD(P)H oxidase inhibition - -
Tert-butyl hydroperoxide (TBHP) - Free-radical generation - -





















Figure 2 Interrelationships of drug-response profiles of yeast deletion mutants. Left panel: Hierarchical clustering of the response of the
heterozygous and homozygous deletion mutants of the HPGI set to treatment with a panel of anti-cancer compounds. Right panel: Comparison
of the drug-response profiles for the heterozygous and homozygous mutants of those HPGI genes for which cancer drug sensitivity differs
markedly according to gene copy number.
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http://www.biomedcentral.com/1741-7007/11/24CNVs, this would suggest a contraindication for treatment
with the particular drug. In particular, the NBP2/nbp2
heterozygote is multiply drug-hypertolerant, of note since
its ortholog SH3GL1 frequently has reduced copy-number
in serous cystadenocarcinoma.
Conversely, for PNP1, the heterozygotes are mitoxantrone/
methotrexate/aminopterin and vorinostat/Bay11/can-
tharidin sensitive, and the homozygotes resistant. This
phenotype may be a instance of ‘obligate haploinsufficiency’
[42], whereby fitness is compromised as the gene dosage is
reduced below some threshold value, but the phenotype issubsequently rescued through the switching on of a
compensatory pathway.
Discussion
The data presented here for the S.cerevisiae HPGI set
point to the striking result that copy-number variation
(in this case, deletion of just one gene copy from a
diploid cell), rather than complete gene loss, is sufficient
to elicit deleterious phenotypes, in particular those
reminiscent of cancer in mammalian cells. This concurs
with the increasing appreciation of the significance of
Cell death
Resistance & increased tumorigenicity
WT S. cerevisiae cell Cell death
Resistance/hypertolerance
b.) CNV & drug sensitivity
Cell death






Sensitivity relative to WT







Null deletion phenotype (e.g. inviability); not   
correlated with heterozygous phenotype
Faster-than-WT growth














Figure 3 The relevance of haploproficiency and hypertolerance to drug interventions. a) specific inhibition, but not complete protein-
product ablation, of an HP target prompts increased growth; b) case where the cancer cell itself bears a CNV of an HP gene, the deletion mutant
phenotype may better predict cancer cell drug response; c) case where the deletion mutant for a specific gene is hypertolerant to a compound
inhibiting a distinct target, a combination therapy of the same compound plus an inhibitor of the first gene is unlikely to elicit a positive
therapeutic response.
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disease. In particular, there is a general lack of significant
correlation of phenotypes between the heterozygous and
homozygous (null) deletion mutants of a given gene.
Nor are the phenotypes of the null mutants necessarily
more extreme than those of the heterozygous deletants,
as might naively be expected from a linear ‘dosage
hypothesis’ [43]. This emphasises the need to systematicallyinvestigate the phenotypic impact of gene dosage, rather
than relying on knockout, or total-knockdown, studies.
A mechanism by which heterozygous deletion of a
gene could be just as disruptive as a complete knockout
is via the disruption of the stoichiometric ratios of the
sub-units of protein complexes. This has been proposed
as a mechanism for haploinsufficiency in the 'balance
hypothesis' of Papp et al. [44-46]. It also suggests that
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zygous deletion of a gene is mitigated by the increased
expression of the remaining copy, does not play a signifi-
cant role amongst our HPGI gene set. Indeed, [47]
showed that such dosage compensation is, in general,
rare in S.cerevisae, and very few HP genes are amongst
those exhibiting significant compensation.
For cell cycle phasing, heterozygous gene deletion is
often sufficient to perturb the cycle from the WT profile,
which indicates that cell cycle proteins are required in
yeast at greater than 50% of WT dosage (the quantitative
relationship between gene copy number and cell cycling
is further explored in [10]). Similarly, heterozygous
deletion of the yeast ortholog is, in general, both
sufficient to alter the degree of apoptosis occurring in
response to DNA-damaging agents (for 15 out of 30
HPGI genes), and to elicit the same apoptotic phenotype
(in 8 out of 15 cases) as is reported for complete
protein-product knockdown in mammalian cells. This
general conservation of apoptotic phenotypes suggests
that the DNA damage-related pathway(s) controlling
apoptosis in S.cerevisiae are similar to those in mammals.
This could be investigated further by undertaking a global
survey of the effect of gene deletion on apoptosis rates in
yeast, particularly since the current data on the degree of
apoptosis in S.cerevisiae is limited (SGD, for example,
reports altered apoptotic phenotypes for only 37 null/con-
ditional mutants and 13 overexpression strains, none of
which are in the HPGI set). In four cases, an altered apop-
tosis rate was observed in the yeast deletion mutants but
has not, so far, been reported for the RNAi knock-downs
of their human orthologs. We would suggest that, based
on the apparent predictive value of the yeast phenotype,
these genes should become the focus of an RNAi study in
mammalian cells.
HP genes and the efficacy of anti-cancer drugs
This critical importance of considering gene dosage in
the context of pharmaceutical intervention in cancer is
further emphasised in the copy-number-dependence of
drug sensitivity phenotypes that we observed with our
yeast model. The mechanisms by which copy-number
variation may exert a significant effect on phenotype are
summarised in Figure 3.
Firstly, products of the mammalian orthologs of
several of the yeast HPGI set are the targets of specific
drugs used, or proposed for use, in treating cancers. Our
data suggest that, in a majority of such cases, complete
inhibition of the activity of a target protein product is
necessary to achieve a positive therapeutic outcome.
Incomplete inhibition, analogous to heterozygous dele-
tion of the gene encoding the target, prompts increased
proliferation or hypertolerance – the opposite of the
intended anti-cancer effect. Furthermore, even if a givengene is not the intended specific target of a chemothera-
peutic treatment, the modes-of-action, and secondary im-
pacts, of many cancer drugs have not been fully elucidated.
Drug-induced haploinsufficiency (or haplotolerance) data
from yeast can contribute to a better understanding of both
drug mechanisms and the functional conservation of drug-
metabolism pathways between yeast and humans. For
example, the clustering of mutant phenotypes in response
to the mammalian-NF-κB inhibitors in this study suggests
that all three compounds act through a common pathway
in S.cerevisiae, which may be mediated by Rad54p.
Secondly, we observed that varying the copy number
of the yeast ortholog can significantly alter the pheno-
typic response to drug treatment. This is especially for
genes whose human orthologs have a high likelihood of
CNV in tumour cells, In particular, several deletion strains
are either more resistant than the WT, or themselves
hypertolerant in response to a specific drug treatment. The
impact of specific CNVs on drug sensitivity is becoming
increasingly appreciated, and we believe our yeast mutant
approach represents a high-throughput complement to the
creation of drug-CNV profile ‘fingerprints’ for tumour cells
(see e.g. [48]), and a model for determining the most
effective drug interventions for tumours with a particular
CNV profile.
Lastly, our data on the sensitivity/resistance of deletion
mutants could potentially inform the design of combination
therapies. Where a particular (heterozygous) deletion
mutant is sensitive to a given drug, a combination therapy
consisting of that drug plus an inhibitor of the product of
the heterozygous gene could have a synergistic effect in
reducing cell proliferation. Conversely, considering pairs
of genes/drugs for which the deletion mutant is resistant
to treatment could assist in identifying those drug
combinations which are unlikely to succeed, reducing
the search space involved in an otherwise expensive
combinatorial problem [49].
Finally, the several instances in which we observed that
the heterozygous deletion mutant is more sensitive to drug
treatment than the homozygote provide evidence for the
‘obligate haploinsufficiency’ hypothesis of Berger et al. [42].
Identifying such genes, and defining the protein product
threshold below which their associated compensatory
pathways are activated, could help to define the precise
inhibitor dosage to achieve maximal therapeutic efficacy.
Conclusions
Haploproficient (HP) genes and are for which, when one
copy is deleted from a diploid cell, the rate of cell prolifera-
tion is increased. We have demonstrated that, for a subset
of yeast HP genes, heterozygous deletion causes aberrant
cell cycling and altered rates of apoptosis, which are
phenotypes associated with cancer in mammalian cells.
A majority of these yeast genes are the orthologs of
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suggest that CNV of these oncogenic orthologs may be
sufficient to lead to tumourigenesis in human cells.
Moreover, where not already implicated, this cluster of
cancer-like phenotypes in this model eukaryote may be
predictive of the involvement in cancer of the mammalian
orthologs of these yeast HP genes. Using the yeast set as a
model, we have shown that the response of the heterozy-
gotes to a range of anti-cancer drugs is strongly dependent
on gene dosage, such that intermediate concentrations of
the drugs can actually increase a mutant’s growth rate. This
suggests such compounds may need to achieve near-total
inhibition of target activity if they are to be a beneficial,
rather than a deleterious, therapy.
Methods
Haploproficient genes and orthology analysis
The set of S.cerevisiae genes which are haploproficient
in turbidostat culture was obtained using the growth
data of [8] and an FDR cutoff of 0.02. This stringent
FDR cut-off rigorously defines those genes for which
heterozygosity confers a strong fitness advantage, but has
no effect on the functional enrichment of genes identified
as haploproficient. Genes defined as ‘haploproficient’ for
the purposes of this study are listed in Additional file 1:
Table S1. The set of chromosome maintenance-associated
HP genes described in [8] overlaps, but is not coincident,
with the HPGI set studied here, since the current set also
includes DNA damage-response genes.
Orthology assignments were made using the InParanoid
algorithm [50] and compared with the results of a BLAST
[51] reciprocal best-hits search. GO enrichment searches
were performed using the Babelomics 4 FatiGO tool [52].
To assess the significance of HP gene conservation,
the number of HP genes having orthologs in a given
Ascomycete species, given the number of S. cerevisiae
HP genes, was compared against the whole-genome
conserved proportion using a χ2 or Fisher exact test
(depending on sample size), with the null hypothesis
of identical distribution. All findings of significance
were reiterated using a Z test for difference of proportions.
Where necessary, P values were corrected for multiple
testing using the Bonferroni correction. Cell cycle and
DNA damage repair pathways were obtained from the
KEGG pathway database [53].
Expression data for S.cerevisae genes was obtained from
the Saccharomyces Genome Database [54]; and protein
expression levels from [55]. A list of human cancer genes/
oncogenes was obtained from the Cancer Gene Index
[17]; enrichment of HP genes amongst the orthologs was
determined using a χ2 test as above. CNV incidence across
eight tumour types (breast invasive carcinoma, rectum
adencarcinoma colon adenocarcinoma, kidney renal cell
clear carcinoma, uterine corpus endometrioid carcinoma,glioblastoma multiforme, acute myeloid leukemia, lung ade-
nocarcinoma, lung squamous cell carcinoma, serous cys-
tadenocarcinoma) as measured by comparative genomic
hybridisation, was obtained from the NCI Cancer Genome
Atlas online data browser [17] with a copy number (log2
ratio) of magnitude >0.5 taken as the significance threshold.
Details of the sampling and analysis of the tumour samples
are described in [17]. A P-value for HP ortholog overrepre-
sentation was calculated using a χ2 test .The TGCA data-
base was also used to perform a pathway search for
overrepresentation of HP orthologs.
Yeast strains
In total, 30 HP genes were chosen for analysis, based upon
the criteria discussed in the Results above. The heterozy-
gous deletion mutant of each gene was obtained from the
heterozygous diploid deletion library (Open Biosystems),
in the BY4743 (MATa/α, his3D1/his3D1, leu2D0/leu2D0,
LYS2/lys2D0, met15D0/MET15, ura3D0/ura3D0) genetic
background. For non-essential genes, the homozygous
deletant was retrieved from the analogous homozygous
diploid deletion library (Open Biosystems).
Control strains were the BY4743 WT, along with the
heterozygous deletion mutant of the non-functional his3
locus; the non-HP, non-cell cycle ho/HO heterozygous
deletion strain; and the heterozygous deletion mutant of
the non-HP, cell cycle gene HSL1. In addition, heterozygous
deletion mutants of the G1 and G2 cyclins were included
in several of the experiments. A complete list of the strains
used is provided in Additional file 6: Table S6.
Cell-cycle profiling
Flow cytometric analysis of the deletion strains’ cell cycle
profiles was carried about following the method of [56].
Briefly, ~107 cells in mid-exponential phase were harvested,
washed, and fixed in absolute ethanol at 4C overnight.
Fixed cells were then collected, washed, and boiled for 15
minutes in 2 mg/mL RNAse in 50 mM Tris-Cl (pH 8), and
incubated at 37C for 2–12 hours. Cells were resuspended
in protease solution (5 mg/mL pepsin, 4.5 μL/mL concen-
trated HCl), incubated for 15 minutes at 37C and
resuspended in 50 mM Tris (pH 7.5). For analysis, 50 mL
of cell suspension was added to 1 mL of 1 mM Sytox Green
in 50 mM Tris pH 7.5), vortexed and analysed using a Cyan
flow cytometer (Beckman Coulter). FlowJo (Tree Star) ana-
lysis software was used to fit histograms to the peaks
representing 1C and 2C DNA content, and thereby calcu-
late the number of cells in the G1 and G2 phases, and infer
the number in S phase from the remaining fraction of the
population.
Chronological lifespan assay
Cultures were inoculated from frozen stocks, grown over-
night in YPD at 3°C, and 200mL of each was transferred
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were present in duplicate on each plate, with a buffer of
WT in the wells around the edge of the plate, so edge
effects would not impact test colony measurements. A
Singer Rotor HDA colony pinning robot was used to spot
four replicates of each well onto a YPD+ 10 μg/mL
phloxine B (Sigma) plate. Phloxine B is a fluorescein deriva-
tive taken up when the cell membrane is disrupted upon
cell death [57]. Plates were incubated for 48 hours at 3°C
and photographed using an Epson 1240 Scanner. The col-
ony images were analysed using a custom image-analysis
code written in MatLab, with colony size measured by pixel
count, and fraction of dead cells by the intensity of colony
redness [10]. Since these parameters are independent, this
allowed the dissection of the effect of cell viability
upon colony growth from that of growth rate variation.
The 96-well liquid cultures were incubated at 3°C, and,
every second day over a period of three weeks, the
colony-pinning onto YPD + phloxine B and image analysis
repeated. For each plate, the median culture intensity for
each strain was compared with the growth of the WT on
that plate, and also with the strain growth and viability
after the initial 48-hour period. The experiment was
performed twice.
At several points throughout the 3-week period, several
strains were selected at random, and viability assayed by
performing serial dilutions and counting colony-forming
units. These results were checked for compatibility with
the microplate viability results.
Apoptosis assays
The rate of occurrence of apoptosis in the different
strain populations was measured in two ways. Apoptosis
was first induced by pretreating cells with 0.001%, 0.01%
MMS, 0.0001% or 0.001% TBHP in overnight culture;
keeping a negative, non-induced WT control sample.
The translocation of phosphatidyl serine to the cell
surface, a marker of apoptosis [58], was measured using
an Annexin V-FITC Apoptosis Detection kit. (Sigma).
Cells were harvested, washed in 1.2M sorbitol, 0.5 mM
MgCl2, 35 mM K phosphate (pH 6.8) and then digested in
5.5% glusulase (Sigma) and 15 U/mL lyticase (Sigma) for
2 hours at 28C. Spheroplasts were harvested, washed in
binding buffer (10 mM Hepes/NaOH pH 7.4, 140 mM
NaCl, 2.5 mM CaCl2 in 1.2 M sorbitol buffer) and
resuspended in binding buffer/sorbitol. 5 mL of FITC-
labelled annexin V, and 10 mL of 10010 mg/mL pro-
pidium iodide were added to each sample, with control
samples containing 1.) no label, 2.) FITC-annexin V only,
and 3.) PI only. Fluorescence was quantified using a CyAn
(Beckman Coulter). Gates were fitted on the basis of the
the control samples, dividing a log PI versus log FITC plot
into four quadrants: lower left (neither FITC nor PI-
stained) – viable cells; upper left (PI stain only) – necroticcells; lower right (FITC only) – early apoptotic cells; and
upper right (PI and FITC-stained) – late apoptotic cells.
FlowJo software (TreeStar) was used to count the fraction
of the total cell population in each quadrant. The propor-
tion of both necrotic and apoptotic cells for each strain
was normalised to strain viability (i.e. on the basis of the
proportion of cells assigned to the lower-left FITC/PI
quadrant), and the ratio of necrotic:apoptotic cells calcu-
lated. Ratios for each strain were normalised to the WT
value, and the standard deviation across all samples calcu-
lated. Strains having a necrosis:apoptosis ratio further
than 1.5x this standard deviation from WT levels were
deemed to demonstrate abnormal apoptosis rates.
Growth rate and drug sensitivity assays
Growth and drug sensitivity assays were performed both
on solid media and in liquid cultures. For solid assays,
the required drug concentration was added to YPD-agar
containing 10μg/m/mL phloxine B. Overnight cultures
of the strains were spotted onto the (drug-containing)
plates using a Singer rotor, as above. Plates were incu-
bated at 3°C and photographed at 24 and 48 hours and
analysed using an image-processing code as described
above. Strain growth and viability was compared both
with WT growth on the same plate, and with growth on
YPD-agar (or YPD-agar plus DMSO, where the drug is
DMSO-soluble). The ratio of viability and size with and
without drug was calculated for every strain on a plate,
and the standard deviation of all ratios calculated.
Strains having a drug:untreated ratio greater than or less
than two standard deviations from that of the WT were
deemed to be resistant and sensitive, respectively.
Assays in liquid culture were performed by transferring
5mL of overnight culture into each well of a 96-well micro-
titre plate, containing 200 μL of YPD plus the required con-
centration of drug. Absorbance was measured for 30 hours
at 3°C using a BMG Optima platereader, maximum growth
rate calculated using a curve-fitting script written in R, and
the growth rate for each strain compared with that of the
WT in the same plate, and growth in YPD/YPD+DMSO.
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